Genomic

Dataset Information

0

Methotrexate Clearance GWAS


ABSTRACT:

We estimated the plasma clearance of methotrexate from 1279 acute lymphoblastic leukemia (ALL) patients treated on the Children Oncology Group 9904 and 9905 trials (http://clinicaltrials.gov/show/NCT00005585 and http://clinicaltrials.gov/show/NCT00005596). Patients received either a 24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose). Methotrexate clearance was lower in older children (p=7 x 10-7), females (p=2.7 x 10-4), and patients who received a delayed intensification phase (p=0.0022). In a genome-wide analysis, methotrexate clearance was associated with polymorphisms in the SLCO1B1 gene (p=2.1 x 10-11), which encodes for an organic anion transporter. This replicates findings using different schedules of high-dose methotrexate in ALL patients treated on St. Jude protocols. A combined meta-analysis yields a p-value of 5.7 x 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056 (Trevino et al, PMID 19901119 and Ramsey et al, PMID 23233662). This data set includes the dependent variable of methotrexate clearance and all of the SNP data available from arrays.

PROVIDER: phs000637 | dbGaP |

SECONDARY ACCESSION(S): PRJNA213031PRJNA213030

REPOSITORIES: dbGaP

Dataset's files

Source:
Action DRS
GapExchange_phs000637.v1.p1.xml Xml
dbGaPEx2.1.5.xsd Other
Study_Report.phs000637.MTX_Clearance_9900.v1.p1.MULTI.pdf Pdf
manifest_phs000637.MTX_Clearance_9900.v1.p1.c1.HMB.pdf Pdf
datadict_v2.xsl Other
Items per page:
1 - 5 of 15

Similar Datasets

| phs000637.v1.p1 | EGA
2007-03-01 | GSE7146 | GEO
2007-03-01 | E-GEOD-7146 | biostudies-arrayexpress
2009-04-01 | GSE12062 | GEO
2013-01-01 | GSE41998 | GEO
2013-01-01 | E-GEOD-41998 | biostudies-arrayexpress
2024-07-12 | PXD046676 | Pride
2024-07-12 | PXD046738 | Pride
2010-05-21 | GSE21909 | GEO
| phs000426 | dbGaP